Maker of Opiate Withdrawal Treatments Charged with Making False, Unsubstantiated Claims About Detox Products
the defendants made claims that 'Withdrawal Ease' alleviated symptoms of opiate withdrawal and increased the likelihood of a person overcoming opiate dependency
A company that marketed itself as "the leader in home opiate detox since 2009" and its CEO have settled Federal Trade Commission (FTC) charges that the withdrawal treatment claims for their "Withdrawal Ease" and "Recovery Ease" products were false or unsupported by any scientific evidence.
The court order settling the FTC's charges bars Catlin Enterprises, Inc. and George Catlin from making claims about opiate withdrawal, opiate dependency, or other health conditions, including through their product names, unless they possess competent and reliable science to back up those claims.
"Opioid addiction is a scourge that has affected millions of Americans," said Acting FTC Chairman Maureen K. Ohlhausen. "People who struggle with this problem need real help, not phony claims and false promises like the ones peddled by these defendants."
According to the FTC's complaint, the defendants violated the FTC Act by making unsubstantiated claims that Withdrawal Ease: 1) significantly alleviated the symptoms of opiate withdrawal; and 2) significantly increased the likelihood of a person overcoming opiate dependency. The defendants also allegedly misrepresented that clinical studies proved Withdrawal Ease's effectiveness. The complaint charges the defendants with deceptively representing that Recovery Ease significantly alleviated long-term opiate withdrawal symptoms.
The proposed order settling the FTC's complaint prohibits the defendants from making health claims, including claims that their products can alleviate withdrawal symptoms or help with drug dependency, unless the claims are non-misleading and substantiated by scientific evidence.
The order also imposes a $6.6 million judgment against the defendants, which will be suspended based on their inability to pay.
The terms of the order are very similar to those in the FTC's recent case against Sunrise Nutraceuticals, another company that the FTC alleged lacked the necessary scientific evidence to prove its herbal product helped with opiate withdrawal.